Acute thoracic empyema: Clinical characteristics and outcome analysis of video-assisted thoracoscopic surgery  by Chen, Ke-Cheng et al.
Journal of the Formosan Medical Association (2014) 113, 210e218Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.j fma-onl ine.comORIGINAL ARTICLEAcute thoracic empyema: Clinical
characteristics and outcome analysis
of video-assisted thoracoscopic surgery*
Ke-Cheng Chen a,b,c,d, Hsuan-Yu Chen e, Jou-Wei Lin f,
Yu-Ting Tseng c, Shuenn-Wen Kuo d, Pei-Ming Huang d,
Hsao-Hsun Hsu d, Jang-Ming Lee d,*, Jin-Shing Chen c,d,*,
Hong-Shiee Lai d,*a Institute of Biomedical Engineering, College of Engineering, National Taiwan University, Taipei,
Taiwan
b College of Medicine, National Taiwan University, Taipei, Taiwan
c Department of Surgery, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County,
Dou-Liou, Taiwan
d Department of Surgery, National Taiwan University Hospital, National Taiwan University College of
Medicine, Taipei, Taiwan
e Institute of Statistical Science, Academia Sinica, Taipei, Taiwan
f Cardiovascular Center and Health Management Center, National Taiwan University Hospital Yun-Lin
Branch, Yun-Lin County, Dou-Liou, TaiwanReceived 5 August 2013; received in revised form 27 December 2013; accepted 31 December 2013KEYWORDS
empyema;
outcome;
propensity analysis;
video-assisted
thoracoscopic
surgery*The study was conceived and desi
J.-S.C., and H.-S.L. conducted the stu
contributed by K.-C.C., J.-W.L., Y.-T.
Conflicts of interest: The authors hav
* Corresponding authors. Departmen
Taiwan.
E-mail addresses: jangminglee@gm
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Acute thoracic empyema is a common clinical problem worldwide, re-
sulting in substantial morbidity and mortality. The objective of this study was to report its clin-
ical characteristics and to evaluate whether thoracoscopic surgery is associated with a lower
rate of in-hospital mortality compared with nonoperative drainage.
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Thoracoscopic surgery for empyema 211in-hospital mortality, was performed to select patients with equalized potential prognostic
factors in the thoracoscopy and nonoperative groups. The log-rank test was used to compare
the survival time with discharge between the two matched groups.
Results: Multivariate analysis showed that age, malignancy, chronic lung disease, chronic
renal insufficiency, liver cirrhosis, polymicrobial infection, and positive bacterial culture
were risk factors for in-hospital mortality. The propensity score-matched analysis showed
that the in-hospital mortality difference was significant (p Z 0.014) and the KaplaneMeier
survival analysis revealed a higher survival rate to discharge (p < 0.001 by log-rank test),
both favoring thoracoscopy over nonoperative drainage.
Conclusion: Acute thoracic empyema carries a high mortality rate, especially in elderly pa-
tients with coexisting medical conditions and polymicrobial and positive bacterial cultures.
Our study results also showed that thoracoscopy is feasible and might provide better chances
for survival in borderline operable patients than nonoperative drainage.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Acute thoracic empyema is an increasingly serious prob-
lem worldwide. Approximately 60,000 patients develop
thoracic empyema in the United States every year,
resulting in significant morbidity and mortality.1 The
mortality rate from pleural infection is between 10% and
20%; drainage through a chest tube and administration of
antibiotics fail in approximately one-third of patients,
requiring subsequent surgical drainage.2e4 In 1962, the
American Thoracic Society5 described the three phases of
empyema as exudative (Stage I), fibrinopurulent (Stage II),
and organizing (Stage III). Although the optimal thera-
peutic approach for empyema remains undetermined,
surgery has been shown to be an effective treatment
option, especially in multiloculated fibrinopurulent em-
pyema. By contrast, the risks of surgery need to be
balanced against the expected benefits. Empyema man-
agement traditionally has been empirical, but recent
data favor establishing more specific management
guidelines.2e4,6e12
Since its introduction, video-assisted thoracoscopic
surgery (VATS) has become an attractive modality for
treating complicated empyema because of its minimal
invasiveness and satisfactory efficacy.2,4,7e12 Although
mounting clinical evidence shows that VATS is beneficial
for treatment of thoracic empyema, selection bias exists
because surgeons tend to choose patients in better con-
dition to obtain satisfactory outcomes.2,4,6e12 Prospective
randomized controlled trials or propensity analysis studies
can correct this bias. However, due to the heteroge-
neousness of patients with different backgrounds consti-
tuting the group and with most of them presenting with
emergency conditions, it is difficult to conduct a ran-
domized controlled trial. In this study, we used our 10-
year experience in managing a large population of acute
thoracic empyema patients (Stage II), focusing on the
analysis of risk factors, and examining the therapeutic
effect of thoracoscopic surgery by propensity analysis,
and compared the results with nonoperative drainage on
an in-hospital mortality and survival time to discharge
basis.Materials and methods
Patient demographic and clinical features
The medical records of all patients with acute thoracic
empyema at the National Taiwan University Hospital dur-
ing the period from January 2001 to June 2010 were
reviewed retrospectively. The Research Ethics Committee
of the National Taiwan University Hospital approved this
study and waived the requirement for informed consent
due to its retrospective nature (approval number:
201203037RIC).
The diagnosis of thoracic empyema was made if a patient
had at least one of the following conditions: the presence of
purulent material in the pleural space, positive results for
loculated pleural fluid culture or Gram stain for microorgan-
isms, and biochemical evidence suggestive of empyema.13
Exclusion criteria were empyema caused by esophageal
rupture, mediastinitis, tuberculosis, fungal infection, post-
operativeempyema,andpediatricempyema(age<20years).
Pediatric empyema patients were excluded because the
subgroup is a distinct entity, which usually has better out-
comes than do adult groups.12 In addition, chronic empyema
patients (Stage III)withorwithout bronchopleural fistulawere
excluded.Thedefinitionofchronicempyema is thefinalphase
of empyema in which fibroblasts proliferate on the visceral
and pleural surfaces, producing a thick inelastic pleural peel.
Informationcollected includeddemographic features,clinical
characteristics, microbiologic and laboratory data, radio-
graphic studies, hospital course, intervention modality, and
treatment outcomes.
The algorithm for patient enrollment is shown in Fig. 1.
Based on the selection criteria, 602 patients were included
in the study. The characteristics and demographics of the
patients with thoracic empyema are listed in Table 1. The
mean age was 58.8 years and 471 patients were male
(78.2%). Most patients (499/602; 82.9%) had chronic un-
derlying diseases or associated medical conditions, and the
main cause was parapneumonic effusion (84.4%).
Bacteriologic results from samples obtained from the
empyema specimens or blood showed that 261 patients
(43.4%) had positive cultures. Polymicrobial infections
Figure 1 Algorithm for selection of patients.
212 K.-C. Chen et al.occurred in 43 patients (7.1%) and one-pathogen infections
occurred in 218 patients (36.2%). The most common path-
ogen was Klebsiella pneumoniae (20.7%; found in 67 pa-
tients), which was followed by methicillin-resistant
Staphylococcus aureus (MRSA; 15.1%) in 49 patients (Table
2). When the etiology of empyema was stratified by the
pathogen isolated, we found that K. pneumoniae was the
most common pathogen in patients with empyema caused
by parapneumonic effusion, while MRSA was most common
in patients with empyema due to other causes (Table 2).
Management
All the patients received empiric broad-spectrum intrave-
nous antibiotics as soon as the diagnosis of thoracic em-
pyema was suspected. Once the causative pathogen was
cultured and identified, the antibiotics were adjusted ac-
cording to the antimicrobial sensitivity testing results.
Sonography-guided thoracentesis was performed on all
patients and the aspirates were sent for laboratory exam-
ination. Chest computed tomography was performed to
evaluate the extent of the empyema and the severity of
pulmonary parenchymal lesions. Patients who had fibro-
purulent (Stage II) empyema were included in our study.
The medical team, including physicians and surgeons,selected nonoperative drainage (repeated thoracentesis or
tube thoracostomy) or/and VATS as the methods of
treatment.
VATS procedures
None of the patients underwent open thoracotomy as the
initial treatment. The patients who were treated with VATS
received general anesthesia using double-lumen endotra-
cheal tubes for selective one-lung ventilation. The proce-
dure was performed using a three-port access method.14
Based on preoperative sonography and computed tomog-
raphy, suitable intercostal sites were selected for port
placement. Fluid, loculations, and septa were removed
under endoscopic vision. Adherent peel was carefully
removed from visceral and parietal pleural surface and the
lung was freed circumferentially from the apex to the
diaphragm. Complete decortication of the visceral pleura
and the fissures was performed using an endoscopic dis-
secting device and a peanut dissector, as in open decorti-
cation. At the end of the procedure, one or two chest tubes
were inserted. The abscess and necrotic tissue from the
empyema collection were sent for bacterial cultures and
pathological examination. During the postoperative period,
a chest plain film was arranged to see whether satisfactory
Table 1 Clinical characteristics and treatment outcome
of 602 patients with acute thoracic empyema.
Variables Results
No. (%) or mean (SD)
Age, y 58.8 (17.0)
Male 471 (78.2%)
Ever smoker 357 (59.3%)
Right sided 333 (55.3%)
Comorbidity 499 (82.9%)
Hypertension 184 (30.6%)
Diabetes mellitus 161 (26.7%)
Coronary arterial disease 94 (15.6%)
Malignancy 90 (15.0%)
Old stroke 80 (13.3%)
Chronic lung disease 69 (11.5%)
Chronic renal insufficiency 65 (10.8%)
Liver cirrhosis 63 (10.5%)
Etiology of empyema
Parapneumonic effusion 508 (84.4%)
Obstructive pneumonitis 25 (4.2%)
Intra-abdominal infection 22 (3.7%)
Hepatic hydrothorax 19 (3.2%)
Traumatic thoracic injury 16 (2.7%)
Bloodstream infection 12 (2.0%)
Positive bacterial culture 261 (43.4%)
Thoracoscopic surgery 417 (69.2%)
Total hospital stay, d 30.5 (27.4)
Mortality 77 (12.8%)
SD Z standard deviation.
Thoracoscopic surgery for empyema 213lung expansion or eradication of pleural effusion was
achieved.
Statistical analyses
The primary outcome assessed in this study was in-hospital
mortality. Categorical variables were compared using c2 and
Fisher exact tests, and continuous variables were compared
using the Student t test. Univariate analyses were performed
to assess the associations between each risk factor and in-
hospital mortality. Variables that had a p < 0.1 in the uni-
variate analyses were subjected to multivariate analysis
using a stepwise binary logistic regression. Odds ratios (ORs)
and 95% confidence intervals were calculated to determine
significance by multivariate analysis. A p value < 0.05 was
taken to be significant. Statistical analyses were performed
using SPSS version 18 (SPSS Inc., Chicago, IL, USA), and all
statistical tests were two sided.
Propensity score-matching methods
Propensity score matching is a method used to balance
observed covariates in the two treatment groups. In this
study, the propensity score was the conditional probability
of undergoing thoracoscopic surgery, as a binary dependent
variable, under a set of measurements. Age, sex, para-
pneumonic effusion, hypertension, diabetes mellitus, cor-
onary arterial disease, malignancy, old stroke, chronic lung
disease, chronic renal insufficiency, liver cirrhosis, positivebacterial cultures, and polymicrobial infection were input
into a nonparsimonious multivariable logistic regression
model to predict the effect of thoracoscopy. The predicted
probability derived from the logistic equation was used as
the propensity score for each individual. The 602 patients
were pooled and sorted according to their propensity score
in ascending order. The selection process began from the
first two cases with the lowest propensity score. If one
underwent thoracoscopy and the other underwent nonop-
erative management, both were selected as a matched
pair. If this was not the case, then four cases were
included. In the same way, thoracoscopic and nonoperative
cases were matched by their propensity score in 1:1, 2:2,
3:3, or 4:4 blocks. A patient who did not have a suitable
match within the acceptable rank range was excluded from
further analysis, and the matching process moved down the
sort list until all possible matched pairs were included.15
The selected patients formed well-matched 1:1 pairs in
both groups (thoracoscopic surgery vs. nonoperative
drainage). KaplaneMeier curves, with follow up until hos-
pital discharge, were plotted to show the survival trend.
The log-rank test was used to compare the differences
between the two matched groups. The survival time was
defined as the duration from admission to death in the
mortality cases, and in the survivors, as the duration from
admission to discharge. A logistic regression model was
used for the propensity score calculation using SPSS release
18 (SPSS Inc.). Propensity scores in both the thoracoscopic
surgery and nonoperative drainage groups were used to
draw box plots.
Results
Treatments and outcomes
Of the 602 patients, 417 (69.2%) underwent thoracoscopic
surgery for debridement and drainage of the empyema. The
remaining 185 patients underwent thoracentesis and/or
tube thoracostomy (nonoperative drainage). After treat-
ment, 525 patients survived to discharge, while the
remaining 77 patients (12.8%) succumbed in the hospital. In
the thoracoscopic group, the conversion to thoracotomy
was noted in eight patients (1.9%)ddue to bleeding in five
patients and due to extensive and severe adhesion in three
patientsdand repeated VATS were noted in 10 patients
(2.4%)dsix patients required repeated VATS due to recur-
rent empyema and it was due to bleeding in the remaining
four patients. The median OR time is 116 minutes (range:
50e178 minutes). Regarding postoperative course, most
patients were admitted to intensive care unit with intuba-
tion (411/417; 98.6%). They were extubated and trans-
ferred to the general ward once their condition stabilized.
The postoperative period was 19.0  18.3 days and the
chest-tube drainage period was 16.8  15.9 days. The mean
hospital stay of the total population was 30.5  27.4 days
(Table 1).
To identify the factors associated with in-hospital mor-
tality, the clinical characteristics, bacteriology, and man-
agement between survivors and nonsurvivors were
summarized and compared by univariate analysis. We found
that age, right-sided empyema, history of malignancy,
Table 2 Microorganisms (n Z 324) isolated from 261 patients.
Organisms All isolates
No. (%) (n Z 324)
Isolates from
parapneumonic effusion
No. (%), (n Z 229)
Isolates from other
etiologies
No. (%), (n Z 95)
p
Aerobic and facultative Gram-positive 141 (43.5%) 101 (44.1%) 40 (42.1%) 0.806
MRSA 49 (15.1%) 33 (14.4%) 16 (16.8%) 0.611
MSSA 13 (4.0%) 8 (3.5%) 5 (5.3%) 0.535
MRCNS 8 (2.5%) 6 (2.6%) 2 (2.1%) 1.000
Streptococcus constellatus 21 (6.5%) 19 (8.3%) 2 (2.1%) 0.046
Viridans streptococci 19 (5.9%) 15 (6.6%) 4 (4.2%) 0.604
Streptococcus pneumoniae 9 (2.8%) 6 (2.6%) 3 (3.2%) 0.457
Staphylococcus intermedius 5 (1.5%) 3 (1.3%) 2 (2.1%) 0.632
Other Streptococci 10 (3.1%) 7 (3.1%) 3 (3.2%) 1.000
Enterococci 7 (2.2%) 4 (1.7%) 3 (3.2%) 0.201
Aerobic and facultative Gram-negative 152 (46.9%) 113 (49.3%) 39 (41.1%) 0.181
Klebsiella pneumoniae 67 (20.7%) 60 (26.2%) 7 (7.4%) 0.0001
Pseudomonas aeruginosa 25 (7.7%) 23 (10.0%) 2 (2.1%) 0.012
PDRAB 16 (4.9%) 13 (5.7%) 3 (3.2%) 0.413
Escherichia coli 15 (4.6%) 3 (1.3%) 12 (12.6%) 0.0001
Enterobacteriaceae 13 (4.0%) 2 (0.9%) 11 (11.6%) 0.0001
Proteus mirabilis 6 (1.9%) 4 (1.7%) 2 (2.1%) 0.675
Salmonella spp. 6 (1.9%) 5 (2.2%) 1 (1.1%) 0.675
Haemophilus aphrophilus 4 (1.2%) 3 (1.3%) 1 (1.1%) 1.000
Anaerobes 31 (9.6%) 15 (6.6%) 16 (16.8%) 0.007
Peptostreptococcus spp. 8 (2.5%) 6 (2.6%) 2 (2.1%) 1.000
Fusobacterium spp. 7 (2.2%) 3 (1.3%) 4 (4.2%) 0.201
Prevotella spp. 4 (1.2%) 2 (0.9%) 2 (2.1%) 0.584
Bacteroides spp. 3 (0.9%) 1 (0.4%) 2 (2.1%) 0.207
Veillonella spp. 3 (0.9%) 2 (0.9%) 1 (1.1%) 0.558
Porphyromonas spp. 2 (0.6%) 1 (0.4%) 1 (1.1%) 0.501
Gemella morbillorum 2 (0.6%) 0 2 (2.1%) 0.085
Clostridium perfringens 2 (0.6%) 0 2 (2.1%) 0.085
MRCNS Z methicillin-resistant coagulase-negative Staphylococci; MRSA Z methicillin-resistant Staphylococcus aureus;
MSSA Z methicillin-sensitive S. aureus; PDRAB Z pan-resistant Acinetobacter baumannii.
Table 3 Multivariate logistic regression analysis of risk
factors affecting in-hospital mortality.
Associated variables Odds
ratio
95% confidence
interval
p
Age 1.031 1.008e1.054 0.007
Malignancy 2.873 1.447e5.705 0.003
Chronic lung disease 3.171 1.458e6.897 0.004
Chronic renal
insufficiency
2.258 1.091e4.673 0.028
Liver cirrhosis 5.818 2.335e14.496 <0.001
Polymicrobial
pathogens
3.387 1.512e7.587 0.003
Positive bacterial
culture
4.476 2.180e9.194 <0.001
Thoracoscopic
surgery
0.306 0.166e0.565 <0.001
214 K.-C. Chen et al.coronary arterial disease, chronic lung disease, chronic
renal insufficiency, liver cirrhosis, empyema due to hepatic
hydrothorax, positive bacterial cultures, polymicrobial
infection, and MRSA infection were associated with a
significantly higher rate of in-hospital mortality. By
contrast, patients with the etiology of parapneumonic
effusion and those who underwent thoracoscopy had a
significantly lower rate of in-hospital mortality. Multivar-
iate logistic regression analysis showed that age, malig-
nancy, chronic lung disease, chronic renal insufficiency,
liver cirrhosis, polymicrobial infection, and positive bacte-
rial cultures were risk factors for in-hospital mortality,
while VATS significantly favored survival (Table 3).
Thoracoscopic surgery versus nonoperative
drainage
To analyze the role of thoracoscopic surgery in empyema,
patients were grouped according to whether they received
thoracoscopic surgery or nonoperative drainage. There
were 417 (69.2%) patients in the thoracoscopy group and
185 (30.8%) in the nonoperative group. Patients in the
thoracoscopy group were younger, had a lower percentage
of malignancies and liver cirrhosis, and a lower rate of in-hospital mortality (7.5% vs. 24.9%, pZ 0.001). The survival
time to discharge in survivors between the two groups was
comparable (Table 4). Using the propensity score-matching
method, 148 patients from the thoracoscopy group and 148
Table 4 Clinical characteristics, bacteriology, and treatment outcome between patients undergoing thoracoscopic and
nonoperative management.
Variables Thoracoscopic surgery (N Z 417)
No. (%) or mean (SD)
Nonoperative drainage
(N Z 185)
No. (%) or mean (SD)
p
Age, y 55.9 (16.7) 65.3 (15.7) <0.001
Male 332 (79.6%) 139 (75.1%) 0.310
Ever smoker 241 (57.8%) 116 (62.7%) 0.281
Right sided 223 (53.5%) 110 (59.5%) 0.183
Comorbidity
Hypertension 132 (31.8%) 52 (28.1%) 0.389
Diabetes mellitus 111 (26.7%) 50 (27.0%) 1.000
Coronary arterial disease 62 (14.9%) 32 (17.3%) 0.467
Old stroke 55 (13.2%) 25 (13.5%) 1.000
Malignancy 52 (12.5%) 38 (20.5%) 0.013
Chronic lung disease 43 (10.4%) 26 (14.1%) 0.213
Chronic renal insufficiency 42 (10.1%) 23 (12.4%) 0.397
Liver cirrhosis 32 (7.7%) 31 (16.8%) 0.001
Hemoglobin 11.4 (1.8) 10.0 (1.5) 0.183
Malnutrition 44 (10.6%) 37 (20.0%) 0.003
Albumin 3.5 (1.0) 3.0 (0.8) 0.178
Alkaline phosphatase 195.1 (18.1) 192.2 (20.0) 0.769
Parapneumonic effusion 355 (85.1%) 153 (82.7%) 0.466
Positive bacterial culture 163 (39.1%) 98 (53.0%) 0.002
Polymicrobial pathogens 31 (7.5%) 12 (6.5%) 0.734
Klebsiella pneumoniae infection 45 (10.8%) 22 (11.9%) 0.676
Survival time to discharge in survivors, da 28.7 (22.4) 29.5 (27.3) 0.734
Mortality 31 (7.5%) 46 (24.9%) 0.001
SD Z standard deviation.
a N Z 386 in the thoracoscopy group and N Z 139 in the nonoperative group.
Thoracoscopic surgery for empyema 215patients from the nonoperative group were selected for
further analysis. Baseline characteristics, including age,
sex, etiology, and comorbidity, were all comparable in the
two groups after propensity score matching. The in-hospital
mortality difference between the two groups was signifi-
cant (p Z 0.014; Table 5). The KaplaneMeier survival
analysis revealed a higher survival rate to discharge, fa-
voring thoracoscopic over nonoperative treatment (log-
rank test p < 0.001; Fig. 2).Discussion
The treatment of thoracic empyema in the fibropurulent
stage focuses on infection control in the pleural cavity and
prevention of late pulmonary restriction due to encasement
of the lungs. Antibiotics, pigtail drain insertion, and tube
thoracostomy still play major roles in the initial manage-
ment of empyema. However, by these methods, it is re-
ported that 36e65% of the patients are not cured, even
with a prolonged hospital stay.2,3 VATS, a procedure that is
more effective than tube drainage, is an attractive alter-
native for treating empyema. Our results showed that age,
malignancy, chronic lung disease, chronic renal insuffi-
ciency, liver cirrhosis, polymicrobial infection, and positive
bacterial culture were significant risk factors for mortality,
while VATS was significantly favorable to survival compared
with nonoperative drainage.In our study, most of the empyema patients (499/602,
82.9%) had additional chronic underlying diseases or asso-
ciated medical conditions. For patients with coexisting
cancer, immunity was weakened by the malignancy, which
was associated with a high mortality rate. Moreover, old
age, chronic lung disease, chronic renal insufficiency, and
liver cirrhosis make patients more vulnerable, and thus the
management of thoracic empyema becomes complicated
and difficult.15e18 A possible explanation for the more
difficult course is that these patients’ immunity was
severely compromised so that the retained pus resulted in
sepsis and, finally, multiple organ failure. As a result, the
overall mean hospital stay was long (30.5 days) and the
mortality rate was high.2e4,7,8,11,19 As for the causes of
mortality, septic shock was the most common, comprising
6.7% (28/417) and 20.5% (38/185) in the thoracoscopic
surgery group and the nonoperative group, respectively.
Compared with a previous report in our institute a decade
earlier, we found that the mortality rate was comparable
(12.8% currently vs. 13.5% previously).20
Our study showed that K. pneumoniae was still the most
common pathogen, as with many other empyema patients
in Taiwan.20,21 When taking the etiology of empyema into
consideration, K. pneumoniae was the main causative
pathogen in parapneumonic effusions, while MRSA was
more common in other causes, especially in patients with
liver cirrhosis.15 Compared with the pediatric empyema
studies conducted recently in our institute where the most
Table 5 Propensity analysis baseline characteristics and clinical outcomes between patients undergoing thoracoscopic and
nonoperative management.
Variables Thoracoscopic surgery (N Z 148)
No. (%) or mean (SD)
Nonoperative drainage (N Z 148)
No. (%) or mean (SD)
p
Age, y 63.3 (14.8) 63.5 (16.3) 0.899
Male 110 (72.4%) 111 (73.0%) 1.000
Ever smoker 83 (56.1%) 90 (60.8%) d
Right sided 77 (52.0%) 85 (57.4%) 1.000
Comorbidity
Hypertension 46 (31.1%) 44 (29.7%) 0.900
Diabetes mellitus 44 (29.7%) 39 (26.3%) 0.605
Coronary arterial disease 23 (15.5%) 24 (16.2%) 1.000
Old stroke 17 (11.5%) 22 (14.9%) 0.492
Malignancy 30 (20.3%) 24 (16.2%) 0.452
Chronic lung disease 12 (8.1%) 20 (13.5%) 1.000
Chronic renal insufficiency 19 (12.8%) 19 (12.8%) 1.000
Liver cirrhosis 16 (10.8%) 15 (10.1%) 1.000
Hemoglobin 10.8 (2.0) 10.6 (1.7) 0.355
Malnutrition 18 (12.2%) 20 (13.5%) 0.862
Albumin 3.1 (1.1) 3.2 (0.9) 0.392
Alkaline phosphatase 184.3 (21.1) 185.2 (18.2) 0.695
Parapneumonic effusion 125 (84.5%) 130 (87.8%) 0.501
Positive bacterial culture 74 (50.0%) 71 (48.0%) 0.816
Polymicrobial pathogens 11 (7.4%) 12 (8.1%) 1.000
Klebsiella pneumoniae infection 19 (12.5%) 17 (11.2%) 0.859
Survival time to discharge in survivors, da 25.5 (20.9) 28.9 (22.3) 0.587
Mortality 14 (9.5%) 30 (20.3%) 0.014
SD Z standard deviation.
a N Z 134 in the thoracoscopy group and N Z 118 in the nonoperative group.
Figure 2 KaplaneMeier plot of the survival-to-discharge in the nonoperative and thoracoscopy groups (log-rank test p < 0.001).
The median survival times are 67.0 versus 125.0 days; the 95% confidence interval was 40.8e93.2 days versus 85.7e164.3 days. The
hazard ratio was 16.1.
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Thoracoscopic surgery for empyema 217common pathogen was Streptococcus pneumoniae in chil-
dren, the adult patients encountered more complicated
courses with higher mortality rates.12 Polymicrobial infec-
tion and positive bacterial cultures were independent risk
factors for in-hospital mortality in our study. Bacterial
overgrowth, despite antibiotic therapy and drainage, in-
dicates potentially greater bacterial toxicity or poor host
immunity, resulting in poor outcomes.22,23
One of the most challenging decisions in treating pa-
tients with empyema is to select the optimal intervention
to evacuate the pus and obliterate the pleural space. The
evolutionary stages of pleural empyema are not clearly
defined, but rather represent a continuous spectrum of
events.9 Thoracoscopy provides minimally invasive access
to the pleural space at the initial time and is effective in
evacuating viscous pleural fluid, lysing adhesions to pro-
mote the drainage of locules, and placing chest tubes in
dependent regions of empyema under direct visualiza-
tion.24,25 According to our experience, thoracoscopy drains
most of the loculated empyema with minimal trauma to the
pleural cavity, which is especially beneficial in patients
with complications. Less invasiveness and less surgical
trauma with thoracoscopy also reduce impairment of pa-
tient immunity and inflammatory and cytokine
responses.26e28 Although repeated surgery is sometimes
required for inadequate drainage or bleeding, it has the
advantage of minimal invasiveness. Therefore, we think
that thoracoscopy is justified in selected patients after
proper preoperative management.
Although operation with thoracoscopic surgery is an
attractive tool for fibropurulent empyema, some patients
were too sick to be operated due to conditions such as
septic shock or multiple organ failure. There are also pa-
tients with borderline general condition who may receive
thoracoscopic surgery or nonoperative drainage, depending
on the decision made by the attending physicians and sur-
geons. Borderline operable patients are defined as patients
who are with clinically moderate condition, that is, not too
sick to have surgery nor too well to neglect surgery.
Through propensity score matching, these borderline
operative patients were selected and analyzed. We found
that thoracoscopic surgery is associated with a lower rate
of in-hospital mortality compared with nonoperative
drainage. Therefore, we encourage surgeons to perform
thoracoscopic surgery whenever possible in borderline
operable empyema patients.Study limitations
This study is limited due to its retrospective nature. It could
be argued that the surgeons tended to choose patients with
better general conditions to obtain better outcomes.
Although the multivariate analysis and propensity score-
matching methods showed that VATS was an independent
factor associated with better survival, some residual bias
could still remain. Another limitation is that the treatment
policy was not standardized among physicians and surgeons,
especially for the timing for thoracoscopic intervention. We
believe that a prospective randomized study with precise
definitions of variables and standardized treatment pro-
tocols would be helpful in validating our results.Conclusion
Thoracic empyema represents a clinical challenge with a
high in-hospital mortality rate due to significant comor-
bidity. Risk factors associated with mortality are age,
coexisting underlying diseases, and polymicrobial and pos-
itive bacterial cultures. Our results also suggested that
thoracoscopic surgery is feasible and might provide better
chances for survival in borderline operable patients.
Acknowledgments
The corresponding authors, as the guarantors of the entire
study, have full access to all the data in the study and take
responsibility for the integrity of the data and the accuracy
of the data analysis. This study was supported by research
grants from the National Taiwan University Hospital Yun-Lin
and Chu-Tung Branch, Taiwan (grant nos. NTUHYL 99-G001
and NTUHCT 101-02).
References
1. Light RW. Parapneumonic effusions and empyema. Proc Am
Thorac Soc 2006;3:75e80.
2. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR.
Management of pleural space infections: a population-based
analysis. J Thorac Cardiovasc Surg 2007;133:346e51.
3. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV,
Miller R, et al. U.K. controlled trial of intrapleural streptoki-
nase for pleural infection. N Engl J Med 2005;352:865e74.
4. Luh SP, Chou MC, Wang LS, Chen JY, Tsai TP. Video-assisted
thoracoscopic surgery in the treatment of complicated para-
pneumonic effusions or empyemas: outcome of 234 patients.
Chest 2005;127:1427e32.
5. American Thoracic Society. Management of nontuberculous
empyema. Am Rev Respir Dis 1962;85:935e6.
6. Yu L, Krasna MJ. Parapneumonic empyema. In: Shields TW,
Locicero III J, Reed CE, Feins RH, editors. General thoracic
surgery. Philadelphia: Lippincott Williams & Wilkins; 2009.
pp. 775e9.
7. Solaini L, Prusciano F, Bagioni P. Video-assisted thoracic sur-
gery in the treatment of pleural empyema. Surg Endosc 2007;
21:280e4.
8. Wozniak CJ, Paull DE, Moezzi JE, Scott RP, Anstadt MP, York VV,
et al. Choice of first intervention is related to outcomes in the
management of empyema. Ann Thorac Surg 2009;87:1525e30.
9. Shin JA, Chang YS, Kim TH, Haam SJ, Kim HJ, Ahn CM, et al.
Surgical decortication as the first-line treatment for pleural
empyema. J Thorac Cardiovasc Surg 2013;145:933e9.
10. Chambers A, Routledge T, Dunning J, Scarci M. Is video-assisted
thoracoscopic surgical decortication superior to open surgery
in the management of adults with primary empyema? Interact
Cardiovasc Thorac Surg 2010;11:171e7.
11. Shahin Y, Duffy J, Beggs D, Black E, Majewski A. Surgical
management of primary empyema of the pleural cavity:
outcome of 81 patients. Interact Cardiovasc Thorac Surg 2010;
10:565e7.
12. Chen JS, Huang KC, Chen YC, Hsu HH, Kuo SW, Huang PM.
Pediatric empyema: outcome analysis of thoracoscopic man-
agement. J Thorac Cardiovasc Surg 2009;137:1195e9.
13. Light RW. A new classification of parapneumonic effusions and
empyema. Chest 1995;108:299e301.
14. Chen JS, Chang YL, Cheng HL, Chang YC, Lee YC. Video-assis-
ted thoracoscopic surgery for the diagnosis of patients with
218 K.-C. Chen et al.hilar and mediastinal lymphadenopathy. J Formos Med Assoc
2001;100:213e6.
15. Chen KC, Lin JW, Tseng YT, Kuo SW, Huang PM, Hsu HH, et al.
Thoracic empyema in patients with liver cirrhosis: clinical
characteristics and outcome analysis of thoracoscopic man-
agement. J Thorac Cardiovasc Surg 2012;143:1144e51.
16. Tsai TH, Jerng JS, Chen KY, Yu CJ, Yang PC. Community-ac-
quired thoracic empyema in older people. J Am Geriatr Soc
2005;53:1203e9.
17. Hsieh MJ, Liu YH, Chao YK, Lu MS, Liu HP, Wu YC, et al. Risk
factors in surgical management of thoracic empyema in elderly
patients. ANZ J Surg 2008;78:445e8.
18. Chen CH, Hsu WH, Chen HJ, Chen W, Shih CM, Hsia TC, et al.
Different bacteriology and prognosis of thoracic empyemas
between patients with chronic and end-stage renal disease.
Chest 2007;132:532e9.
19. Marks DJ, Fisk MD, Koo CY, Pavlou M, Peck L, Lee SF, et al.
Thoracic empyema: a 12-year study from a UK tertiary
cardiothoracic referral centre. PLoS One 2012;7:e30074.
20. Chen KY, Hsueh PR, Liaw YS, Yang PC, Luh KT. A 10-year
experience with bacteriology of acute thoracic empyema:
emphasis on Klebsiella pneumoniae in patients with diabetes
mellitus. Chest 2000;117:1685e9.
21. Lin YT, Chen TL, Siu LK, Hsu SF, Fung CP. Clinical and micro-
biological characteristics of community-acquired thoracicempyema or complicated parapneumonic effusion caused by
Klebsiella pneumoniae in Taiwan. Eur J Clin Microbiol Infect
Dis 2010;29:1003e10.
22. Wang CY, Wu VC, Wang WJ, Lin YF, Lin YH, Chen YM, et al. Risk
factors for nasal carriage of methicillin-resistant Staphylo-
coccus aureus among patients with end-stage renal disease in
Taiwan. J Formos Med Assoc 2012;111:14e8.
23. Jean SS, Hsueh PR. Antimicrobial drug resistance in Taiwan. J
Formos Med Assoc 2011;110:4e13.
24. Heffner JE, Klein JS, Hampson C. Interventional management
of pleural infections. Chest 2009;136:1148e59.
25. Cassina PC, Hauser M, Hillejan L, Greschuchna D, Stamatis G.
Video-assisted thoracoscopy in the treatment of pleural em-
pyema: stage-based management and outcome. J Thorac
Cardiovasc Surg 1999;117:234e8.
26. Novitsky YW, Litwin DE, Callery MP. The net immunologic advan-
tage of laparoscopic surgery. Surg Endosc 2004;18:1411e9.
27. Ng CS, Whelan RL, Lacy AM, Yim AP. Is minimal access surgery
for cancer associated with immunologic benefits? World J Surg
2005;29:975e81.
28. Chen KC, Chen JS, Kuo SW, Huang PM, Hsu HH, Lee JM, et al.
Descending necrotizing mediastinitis: a 10-year surgical expe-
rience in a single institution. J Thorac Cardiovasc Surg 2008;
136:191e8.
